Hammond, Danielle http://orcid.org/0000-0002-6017-2264
Loghavi, Sanam http://orcid.org/0000-0001-8980-3202
Wang, Sa A.
Konopleva, Marina Y. http://orcid.org/0000-0002-9347-2212
Kadia, Tapan M. http://orcid.org/0000-0002-9892-9832
Daver, Naval G. http://orcid.org/0000-0001-7103-373X
Ohanian, Maro
Issa, Ghayas C. http://orcid.org/0000-0002-4339-8683
Alvarado, Yesid http://orcid.org/0000-0002-1652-7937
Short, Nicholas J. http://orcid.org/0000-0002-2983-2738
Sasaki, Koji
Pemmaraju, Naveen http://orcid.org/0000-0002-1670-6513
Montalban-Bravo, Guillermo
Lachowiez, Curtis A.
Maiti, Abhishek
Garcia-Manero, Guillermo http://orcid.org/0000-0002-3631-2482
Jabbour, Elias J. http://orcid.org/0000-0003-4465-6119
Borthakur, Gautam http://orcid.org/0000-0001-7679-6453
Ravandi, Farhad http://orcid.org/0000-0002-7621-377X
Takahashi, Koichi http://orcid.org/0000-0002-8027-9659
Pierce, Sherry R.
Kantarjian, Hagop M. http://orcid.org/0000-0002-1908-3307
DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Article History
Received: 20 October 2022
Revised: 13 August 2023
Accepted: 25 August 2023
First Online: 21 September 2023
Competing interests
: DH: None. SL: None. SAW: None. MYK: reports research contributions from Cellectis, Stemline Therapeutics, Ablynx, Forty-Seven, Genentech, Rafael Pharmaceutical, Agios, AstraZeneca, Calithera, Ascentage, AbbVie, Sanofi, Eli Lilly, F. Hoffmann-La Roche, and consultancy contributions to Stemline Therapeutics, Forty-Seven, Genentech, Kosji, AbbVie, Amgen, and F. Hoffmann-La Roche. TMK: research support from AbbVie, BMS, AstraZeneca, Cellenkos, Pfizer, Astellas, Ascentage, Pulmotec, Amgen, Genentech, Celgene, Incyte, Jazz, and Cyclacel, and honoraria from AbbVie, BMS, Pfizer, Novartis, Genentech, and Jazz. ND: research support from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, AbbVie, Hanmi, Trovagene, FATE, Amgen, Novimmune, Glycomimetics, and Immuno-Gen, and consultancy/advisory contributions to Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, and Agios. MO: None. GCI: received research funding from Celgene, Kura Oncology, Syndax, and Novartis and received consultancy fees from Novartis and Kura Oncology. YA: received research funding from FibroGen, BerGenBio ASA, MEI Pharma, Daiichi-Sankyo, Tolero Pharmaceuticals, Sun Pharma, Jazz Pharmaceuticals, and Astex Pharmaceuticals. NJ.S. research support from Takeda Oncology and Astellas Pharma Inc., consultancy support from Takeda Oncology and AstraZeneca, and honoraria from Amgen. KS: reports research contributions from Novartis; consultancy contributions for Pfizer Japan, Novartis, Daiichi Sankyo; and honoraria from Otsuka. NP: reports research contributions from Affymetrix, Stemline Therapeutics, AbbVie, Daiichi Sankyo, Plexxikon, Cellectis, Novartis, Samus Therapeutics; grant support from Affymetrix, SagerStrong; and honoraria from Stemline Therapeutics, LFB Biotechnologies, MustangBio, Incyte Corporation, Celgene, DAVA Oncology, Blueprint Medicines, Novartis, and Roche Diagnostics. GM-B: None. CAL: None. AM: None. GG-M: Research contributions from Celgene, Genentech, Novartis, Merck, Bristol-Myers. Squibb, AbbVie, Helsinn Therapeutics, H3 Biomedicine, Amphivena Therapeutics, Onconova, Astex Pharmaceuticals; consultancy contributions from Celgene, Genentech, Bristol-Myers Squibb, Acceleron Pharmaceuticals, Helsinn Therapeutics, Astex Pharmaceuticals, and Jazz Pharmaceuticals; and honoraria contributions from Celgene, Acceleron Pharmaceuticals, AbbVie, Helsinn Therapeutics, and Astex Pharmaceuticals. EJ: Research contributions from Amgen, Adaptive Biotechnologies, AbbVie, Pfizer, Takeda, BMS, and Genentech, and advisory contributions for Amge, Adaptive Biotechnologies, AbbVie, Pfizer, Takeda, BMS, and Genentech. GB: Research contributions from AstraZeneca, GSK, BMS, AbbVie, Novartis, Incyte, Polaris, Xbiotech USA, Oncoceutics, PTC Therapeutics, Jannsen, Bioline Rx, Cyclacel, and consultancy contributions from PTC Therapeutics, Nkarta Therapeutics, Treadwell Therapeutics, BioTherix, Curio Science LLC, FTC Therapeutics, Argenx, and BioLine Rx. FR: Research support from AbbVie and advisory contributions and honoraria from Celgene and BMS. A.M. reports institutional research support from Celgene. KT: Receives advisory and consultancy fees from Celgene, Novartis, GSK, Symbio Pharmaceuticals, and Kyowa Hakko Kirin. HK: Research contributions from AbbVie, Amgen, Jazz, Daiichi-Sankyo, BMS, Ascentage, Immunogen, Novartis, Pfizer, and Sanofi; advisory contributions for Actinium; and honoraria contributions from Aptitute Health, AbbVie, BioAscend, D Fly, Amgen, Daiichi Sankyo, Adaptive Biotechnologies, Oxford Biomedical, Novartis, Actinium, and Pfizer. G.G.-M. reports research contributions from Celgene, Genentech, Novartis, Merck, Bristol-Myers Squibb, AbbVie, Helsinn Therapeutics, H3 Biomedicine, Amphivena Therapeutics, Onconova, Astex Pharmaceuticals; consultancy contributions from Celgene, Genentech, Bristol-Myers Squibb, Acceleron Pharmaceuticals, Helsinn Therapeutics, Astex Pharmaceuticals, and Jazz Pharmaceuticals; and honoraria contributions from Celgene, Acceleron Pharmaceuticals, AbbVie, Helsinn Therapeutics, and Astex Pharmaceuticals. CDD: Research support from AbbVie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi-Sankyo, ImmuneOnc, andLoxo, and consultancy/advisory contributions for AbbVie, Agios, Celgene/BMS, Foghorn Therapeutics, Gilead, ImmuneOnc, Novartis, Takeda, and Notable Labs.